Becker's Healthcare October 23, 2024
Alexandra Murphy

The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
How America Lost Control of the Bird Flu, Setting the Stage for Another Pandemic
Science magazine names HIV drug its 'Breakthrough of the Year'
Integrating Equity Into Licensing Agreements For Taxpayer-Funded Technologies
How Technology Could Speed And Support Disaster Response
Food recalls seem increasingly common. Why?

Share This Article